Literature DB >> 8390811

Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

S Kaul1, K A Dandekar.   

Abstract

Stavudine was administered (15 mg/kg of body weight) intravenously and orally to two monkeys in a randomized crossover study. Plasma and urine samples were analyzed for stavudine by high-performance liquid chromatography, and pharmacokinetic parameters were derived by a noncompartmental method. Total body clearance of stavudine was 0.64 liters/h/kg, with a steady-state volume of distribution of 0.68 liters/kg, a terminal half-life of 0.83 h, a urinary recovery of 44%, and an oral bioavailability of 80%. These values were reasonably similar to those reported for patients with AIDS or AIDS-related complex.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8390811      PMCID： PMC187922          DOI： 10.1128/AAC.37.5.1160

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine.

Authors:  J S Janiszewski; D E Mulvana; S Kaul; K A Dandekar; R H Barbhaiya
Journal:  J Chromatogr       Date:  1992-05-20

Review 2.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

3.  Dose-ranging pharmacokinetics of zidovudine (azidothymidine) in the rat.

Authors:  J D Unadkat; J P Wang; D Pulham; R L Semmes
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

4.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex.

Authors:  O L Laskin; P de Miranda; M R Blum
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

Review 6.  Preclinical toxicology of zidovudine. An overview.

Authors:  K M Ayers
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

Review 7.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  Thymidine catabolism and the reutilization of its degradative products in Tetrahymena pyriformis. Metabolism of [2,6-14C2]thymidine and [2-14C]methylmalonic acid.

Authors:  M A Niemann; J Berech
Journal:  Biochim Biophys Acta       Date:  1981-02-26

9.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats.

Authors:  B A Patel; C K Chu; F D Boudinot
Journal:  J Pharm Sci       Date:  1989-07       Impact factor: 3.534
View more
  7 in total

1.  In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina).

Authors:  A Odinecs; C Nosbisch; R D Keller; W L Baughman; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina).

Authors:  A Odinecs; C Pereira; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Authors:  S Kaul; B Christofalo; R H Raymond; M B Stewart; C M Macleod
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2',3'-didehydro-3'-deoxythymidine) in the pigtailed macaque (Macaca nemestrina).

Authors:  A Odinecs; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Aleksandr Obikhod; David Delinsky; Janarthanan Narayanasamy; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

6.  Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina).

Authors:  R D Keller; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 7.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.